Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,029 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Rossat J, et al. Among authors: burnier m. Clin Pharmacol Ther. 1999 Jul;66(1):76-84. doi: 10.1016/S0009-9236(99)70056-1. Clin Pharmacol Ther. 1999. PMID: 10430112 Clinical Trial.
Neurohormonal consequences of diuretics in different cardiovascular syndromes.
Burnier M, Brunner HR. Burnier M, et al. Eur Heart J. 1992 Dec;13 Suppl G:28-33. doi: 10.1093/eurheartj/13.suppl_g.28. Eur Heart J. 1992. PMID: 1362543 Review.
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.
Burnier M, Biollaz J. Burnier M, et al. Clin Pharmacokinet. 1992 May;22(5):375-84. doi: 10.2165/00003088-199222050-00004. Clin Pharmacokinet. 1992. PMID: 1505143 Review.
Evaluation of arterial compliance-pressure curves. Effect of antihypertensive drugs.
Perret F, Mooser V, Hayoz D, Tardy Y, Meister JJ, Etienne JD, Farine PA, Marazzi A, Burnier M, Nussberger J, et al. Perret F, et al. Among authors: burnier m. Hypertension. 1991 Oct;18(4 Suppl):II77-83. doi: 10.1161/01.hyp.18.4_suppl.ii77. Hypertension. 1991. PMID: 1680813 Clinical Trial.
Antihypertensive therapy and mobilization of renal functional reserve.
Burnier M, Biollaz J, Steinhauslin F, Brouard R, Waeber B, Brunner HR. Burnier M, et al. Clin Invest Med. 1991 Dec;14(6):581-9. Clin Invest Med. 1991. PMID: 1686579 Review.
Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition.
Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR. Mooser V, et al. Among authors: burnier m. J Cardiovasc Pharmacol. 1990 Feb;15(2):276-82. doi: 10.1097/00005344-199002000-00015. J Cardiovasc Pharmacol. 1990. PMID: 1689424 Clinical Trial.
Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.
Burnier M, Ganslmayer M, Perret F, Porchet M, Kosoglou T, Gould A, Nussberger J, Waeber B, Brunner HR. Burnier M, et al. Clin Pharmacol Ther. 1991 Aug;50(2):181-91. doi: 10.1038/clpt.1991.123. Clin Pharmacol Ther. 1991. PMID: 1831083 Clinical Trial.
Role of atrial natriuretic peptides and neuropeptide Y in blood pressure regulation.
Waeber B, Burnier M, Nussberger J, Brunner HR. Waeber B, et al. Among authors: burnier m. Horm Res. 1990;34(3-4):161-5. doi: 10.1159/000181817. Horm Res. 1990. PMID: 2151774 Review.
Trials using a crossover design and ambulatory blood pressure recordings to determine the efficacy of antihypertensive agents in individual patients.
Waeber B, Burnier M, Nussberger J, Brunner HR. Waeber B, et al. Among authors: burnier m. J Hypertens Suppl. 1990 Sep;8(4):S37-41. J Hypertens Suppl. 1990. PMID: 2258782 Clinical Trial.
Bolus injections of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndrome.
Burnier M, Mooser V, Wauters JP, Marder HK, De Vane P, Nussberger J, Waeber B, Brunner HR. Burnier M, et al. J Cardiovasc Pharmacol. 1989 May;13(5):682-90. J Cardiovasc Pharmacol. 1989. PMID: 2472515 Clinical Trial.
1,029 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page